Addenbrooke’s Hospital in Cambridge has become the first NHS centre to pioneer a new generation of immunotherapy for patients with an aggressive form of skin cancer. This is the latest in a series of campaigns to tackle cancer by investing in technology, research and education.
Cambridge University Hospitals (CUH) is one of the largest and best known hospitals in the country, delivering high-quality patient care through Addenbrooke’s and the Rosie Hospitals. Addenbrooke’s is now participating in a global research study to treat patients with advanced melanoma, which hasn’t responded to conventional treatments.
The study, harnessing immune cells called Tumour Infiltrating Lymphocytes (TILs), began in the USA and is now being brought to limited European specialist centres. Addenbrooke’s is the first NHS centre.
Sponsored by US-based Iovance Biotherapeutics Inc., it involves surgically removing some melanoma tumour tissue, separating out the TILs and growing them in a centralised production facility for approximately three weeks. Then they are returned to the hospital and administered to the patient via intravenous infusion.
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.
